About this trial
Individuals who have insomnia with short sleep duration (ISS) differ from individuals who have insomnia with normal sleep duration (INS) in terms of health risks (i.e., hypertension) and treatment response. This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive Behavioral Therapy for Insomnia (CBT-I). The other is a widely prescribed, non-habit-forming medication, trazodone used at a low dose. The investigators' findings could lead to evidence-based treatment guidelines that help clinicians more effectively match treatments to insomnia patients and reduce associated health problems.
Eligibility criteria
Qualifiers
Age 18 or older
Able to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site.
Meets criteria for chronic insomnia
Body Mass Index (BMI) 18.5 kg/m2 and higher
Disqualifiers
Age < 18
Unable to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site.
Unwilling to share email address/cell phone number to accept survey links.
Life time diagnosis of psychotic or bipolar disorder
Trial design
Treatments tested in this trial
- Cognitive Behavioral Treatment for Insomnia (CBT-I)
- Trazodone
- Placebo
Treatment groups
Sponsors and collaborators
Milton S. Hershey Medical Center
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator